Information de reference pour ce titreAccession Number: | 00004686-201107000-00027.
|
Author: | Lehmann, Brian D. 1; Bauer, Joshua A. 1; Chen, Xi 2; Sanders, Melinda E. 3; Chakravarthy, A. Bapsi 4; Shyr, Yu 2; Pietenpol, Jennifer A. 1
|
Institution: | (1)Department of Biochemistry, (2)Department of Biostatistics, (3)Department of Pathology, and (4)Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
|
Title: | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.[Article]
|
Source: | Journal of Clinical Investigation. 121(7):2750-2767, July 1, 2011.
|
Abstract: | Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify molecular-based therapies. In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases. Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. Further, GE analysis allowed us to identify TNBC cell line models representative of these subtypes. Predicted "driver" signaling pathways were pharmacologically targeted in these cell line models as proof of concept that analysis of distinct GE signatures can inform therapy selection. BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin. M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor). The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist). These data may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies.
Copyright (C) 2011 The American Society for Clinical Investigation, Inc.
|
References: | 1. Pegram MD, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 16 8 2659-2671
2. Wiggans RG, et al. Phase-II trial of tamoxifen in advanced breat cancer. Cancer Chemother Pharmacol. 1979 3 1 45-48
3. Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007 13 8 2329-2334
4. Morris GJ, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007 110 4 876-884
5. Haffty BG, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006 24 36 5652-5657
6. Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 13 15 pt 1 4429-4434
7. D'Andrea AD, Grompe M The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003 3 1 23-34
8. Hoeijmakers JH Genome maintenance mechanisms for preventing cancer. Nature. 2001 411 6835 366-374
9. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 434 7035 917-921
10. Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 361 2 123-134
11. Burstein HJ, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 26 11 1810-1816
12. Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 10 16 5367-5374
13. Finn RS, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007 105 3 319-326
14. Ellard SL, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009 27 27 4536-4541
15. Carmeci C, deConinck EC, Lawton T, Bloch DA, Weigel RJ Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology. Am J Pathol. 1997 150 5 1563-1570
16. Press MF, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008 14 23 7861-7870
17. Bertucci F, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008 123 1 236-240
18. Rakha EA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009 15 7 2302-2310
19. Monti S, Tamayo P, Mesirov J, Golub T Consensus clustering: A resampling-baased method for class discovery and visualization of gene expression microarray data. Machine Learning. 2003 52 1-2 91-118
20. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 102 43 15545-15550
21. Chakravarthy AB, et al. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res. 2006 12 5 1570-1576
22. Bauer JA, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010 16 2 681-690
23. Juul N, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010 11 4 358-365
24. Bertucci F, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006 66 9 4636-4644
25. Gibson GR, Qian D, Ku JK, Lai LL Metaplastic breast cancer: clinical features and outcomes. Am Surg. 2005 71 9 725-730
26. Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010 12 5 R68
27. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008 14 13 4038-4044
28. Chen CD, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004 10 1 33-39
29. Farmer P, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005 24 29 4660-4671
30. Hu Z, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006 7 96
31. Yang XR, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst. 2011 103 3 250-263
32. Kenny PA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2007 1 1 84-96
33. Neve RM, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 10 6 515-527
34. Agoff NS, Swanson PE, Linden H, Hawes SE, Lawton TJ Androgen receptor expression in estrogen receptor-negative breast cancer. Am J Clin Pathol. 2003 120 5 725-731
35. Marty B, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008 10 6 R101
36. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000 275 31 23899-23903
37. Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 52 22 7170-7185
38. Evers B, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008 14 12 3916-3925
39. Solit DB, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 8 5 986-993
40. Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 304 5670 554
41. Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008 7 7 1851-1863
42. Kreike B, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007 9 5 R65
43. Rakha E, Ellis I, Reis-Filho J Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res. 2008 14 2 618
44. Stefansson OA, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 2009 11 4 R47
45. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010 4 3 255-266
46. Silver DP, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 28 7 1145-1153
47. Audeh MW, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009 27 5500
48. Garber JE, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative" breast cancer. Breast Cancer Res Treat. 2006 105 S149
49. Telli ML, Ford JM Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer. 2010 10 suppl 1 E16-E22
50. Mayer IA, et al. A phase II newoadjuvant negative (TN) locally advanced breast cancer (BC). J Clin Oncol. 2010 28 1 15
51. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007 8 8 R157
52. Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 133 4 704-715
53. Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 11 3 259-273
54. Hennessy BT, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009 69 10 4116-4124
55. Guarino M Src signaling in cancer invasion. J Cell Physiol. 2010 223 1 14-26
56. Shin SY, et al. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res. 2010 70 17 6715-6724
57. MacDonald BT, Tamai K, He X Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009 17 1 9-26
58. Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006 25 28 3994-4008
59. Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007 21 10 2285-2293
60. Memorial Sloan-Kettering Cancer Center and National Cancer Institute (NCI). Bicalutamide in treating patients with metastatic breast cancer. NIH Web site. http://clinicaltrials.gov/ct2/sh...- ouverture dans une nouvelle fenêtre . Accessed April 14, 2011.
61. Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009 15 7 2472-2478
62. Stemke-Hale K, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 68 15 6084-6091
63. Liu X, Gomez-Pinillos A, Ferrari AC Simultaneous targeting of the androgen receptor and PI3K/mTOR pathway in androgen-dependent and androgen-independent prostate cancer cells. J Clin Oncol. 2010 28 (suppl; abstr e15049 )
64. Karn T, et al. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat. 2010 120 3 567-579
65. Bauer JA, et al. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010 12 3 R41
66. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005 102 38 13550-13555
67. Richardson AL, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006 9 2 121-132
68. Desmedt C, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007 13 11 3207-3214
69. Chin K, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006 10 6 529-541
70. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005 365 9460 671-679
71. Sotiriou C, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006 98 4 262-272
72. Pawitan Y, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005 7 6 R953-R964
73. Schmidt M, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008 68 13 5405-5413
74. Minn AJ, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005 436 7050 518-524
75. Yu K, et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet. 2008 4 7 e1000129
76. Boersma BJ, et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer. 2008 122 6 1324-1332
77. Bos PD, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009 459 7249 1005-1009
78. Li Y, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010 16 2 214-218
|
Language: | English.
|
Document Type: | Research Article.
|
Journal Subset: | Clinical Medicine. Medical Humanities.
|
ISSN: | 0021-9738
|
NLM Journal Code: | hs7, 7802877
|
DOI Number: | https://dx.doi.org/10.1172/JCI45...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|